Longeveron (Longeveron) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 13, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Longeveron EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Longeveron's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Longeveron's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Longeveron's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longeveron's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Longeveron's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Longeveron (NAS:LGVN) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Longeveron EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Longeveron's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Longeveron (Longeveron) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136

Website

https://www.longeveron.com

Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The company has generated revenue from three sources: 1) Grant awards. 2) The Bahamas Registry Trial. 3) Contract development and manufacturing services.

Executives

Cathy Ross	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Khoso Baluch	director	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Jeffrey Pfeffer	director
Lisa Locklear	officer: Chief Financial Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova	officer: Chief Medical Officer	1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo	officer: CFO and Treasurer	1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Hashad Mohamed Wa'el Ahmed	officer: Chief Executive Officer	SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare	director, officer: Chief Scientific Officer	C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Kwan-hong Christopher Min	officer: Chief Medical Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green	officer: CEO	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr	officer: General Counsel, Secretary	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer	director, 10 percent owner	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136